Arnold Offers Thin-Rolled Titanium Foils and Alloys in a Broad Range of Thicknesses, Widths and Grades for Medical Devices

As wide as 17.5” and as thin as 2µm (0.00008”) with controlled, consistent quality

Arnold Magnetic Technologies Corporation (“Arnold”), a subsidiary of Compass Diversified (NYSE: CODI) and leading global manufacturer of high-performance magnets, magnetic assemblies, precision thin metals and highly loaded composites, announces its range of titanium foils and alloys. Arnold offers thin cold-rolled titanium in a variety of CP Grades and alloys and an exceptionally broad range of thicknesses and widths for many applications, including medical devices, that require a strong, lightweight, corrosion-resistant, biocompatible material that is highly workable, ductile, and weldable. Arnold’s range of products can be found across the medical industry, from advanced diagnostic, laboratory and surgical equipment to prosthetics, implants, drug delivery systems and radiation shielding.
As the global leader in ultra-thin cold-rolled metal strip and foil, Arnold achieves unmatched thinness while maintaining controlled, consistent mechanical and physical quality. Arnold’s “Ultra Thin Gauge” foil is available in thickness down to 2 µm (0.00008“), in addition to the “Thin Gauge” options (0.020“ – 0.0005“).
Widths are available up to 17.5”, depending on thickness. For example, foil 0.0029” – 0.001” thick has a maximum width of 16.5”. Widths as narrow as 0.031” can be achieved through slitting.
Arnold offers multiple Commercially Pure (CP) grades with 99%+ pure titanium. Options include Grade 1 which has the highest purity of commercially available titanium with excellent corrosion resistance to chlorides, and Grade 2, the most commonly specified grade of CP titanium, which has good ductility with excellent corrosion resistance especially to seawater and Grade 4 which is the strongest CP grade and is certified per AMS standards.
Available titanium alloys include Grade 9, 15-3-3-3, Grade 23, and Beta21s, a high strength material engineered specifically to improve resistance to oxidation and creep along with enhanced elevated temperature strength and stability.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”